Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 4 of 4 entries
Sorted by: Best Match Show Resources per page
Standardizing global gene expression analysis between laboratories and across platforms.

Nature methods

Bammler T, Beyer RP, Bhattacharya S, Boorman GA, Boyles A, Bradford BU, Bumgarner RE, Bushel PR, Chaturvedi K, Choi D, Cunningham ML, Deng S, Dressman HK, Fannin RD, Farin FM, Freedman JH, Fry RC, Harper A, Humble MC, Hurban P, Kavanagh TJ, Kaufmann WK, Kerr KF, Jing L, Lapidus JA, Lasarev MR, Li J, Li YJ, Lobenhofer EK, Lu X, Malek RL, Milton S, Nagalla SR, O'malley JP, Palmer VS, Pattee P, Paules RS, Perou CM, Phillips K, Qin LX, Qiu Y, Quigley SD, Rodland M, Rusyn I, Samson LD, Schwartz DA, Shi Y, Shin JL, Sieber SO, Slifer S, Speer MC, Spencer PS, Sproles DI, Swenberg JA, Suk WA, Sullivan RC, Tian R, Tennant RW, Todd SA, Tucker CJ, Van Houten B, Weis BK, Xuan S, Zarbl H.
PMID: 15846362
Nat Methods. 2005 May;2(5):351-6. doi: 10.1038/nmeth754. Epub 2005 Apr 21.

To facilitate collaborative research efforts between multi-investigator teams using DNA microarrays, we identified sources of error and data variability between laboratories and across microarray platforms, and methods to accommodate this variability. RNA expression data were generated in seven laboratories,...

Cite
Bammler T, Beyer RP, Bhattacharya S, et al. Standardizing global gene expression analysis between laboratories and across platforms. Nat Methods. 2005;2(5):351-6doi: 10.1038/nmeth754.
Bammler, T., Beyer, R. P., Bhattacharya, S., Boorman, G. A., Boyles, A., Bradford, B. U., Bumgarner, R. E., Bushel, P. R., Chaturvedi, K., Choi, D., Cunningham, M. L., Deng, S., Dressman, H. K., Fannin, R. D., Farin, F. M., Freedman, J. H., Fry, R. C., Harper, A., Humble, M. C., Hurban, P., Kavanagh, T. J., Kaufmann, W. K., Kerr, K. F., Jing, L., Lapidus, J. A., Lasarev, M. R., Li, J., Li, Y. J., Lobenhofer, E. K., Lu, X., Malek, R. L., Milton, S., Nagalla, S. R., O'malley, J. P., Palmer, V. S., Pattee, P., Paules, R. S., Perou, C. M., Phillips, K., Qin, L. X., Qiu, Y., Quigley, S. D., Rodland, M., Rusyn, I., Samson, L. D., Schwartz, D. A., Shi, Y., Shin, J. L., Sieber, S. O., Slifer, S., Speer, M. C., Spencer, P. S., Sproles, D. I., Swenberg, J. A., Suk, W. A., Sullivan, R. C., Tian, R., Tennant, R. W., Todd, S. A., Tucker, C. J., Van Houten, B., Weis, B. K., Xuan, S., Zarbl, H. (2005). Standardizing global gene expression analysis between laboratories and across platforms. Nature methods, 2(5), 351-6. https://doi.org/10.1038/nmeth754
Bammler, Theodore, et al. "Standardizing global gene expression analysis between laboratories and across platforms." Nature methods vol. 2,5 (2005): 351-6. doi: https://doi.org/10.1038/nmeth754
Bammler T, Beyer RP, Bhattacharya S, Boorman GA, Boyles A, Bradford BU, Bumgarner RE, Bushel PR, Chaturvedi K, Choi D, Cunningham ML, Deng S, Dressman HK, Fannin RD, Farin FM, Freedman JH, Fry RC, Harper A, Humble MC, Hurban P, Kavanagh TJ, Kaufmann WK, Kerr KF, Jing L, Lapidus JA, Lasarev MR, Li J, Li YJ, Lobenhofer EK, Lu X, Malek RL, Milton S, Nagalla SR, O'malley JP, Palmer VS, Pattee P, Paules RS, Perou CM, Phillips K, Qin LX, Qiu Y, Quigley SD, Rodland M, Rusyn I, Samson LD, Schwartz DA, Shi Y, Shin JL, Sieber SO, Slifer S, Speer MC, Spencer PS, Sproles DI, Swenberg JA, Suk WA, Sullivan RC, Tian R, Tennant RW, Todd SA, Tucker CJ, Van Houten B, Weis BK, Xuan S, Zarbl H. Standardizing global gene expression analysis between laboratories and across platforms. Nat Methods. 2005 May;2(5):351-6. doi: 10.1038/nmeth754. Epub 2005 Apr 21. PMID: 15846362.
Copy Download .nbib Format: NLM
Oxopyrido[2,3-d]pyrimidines as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors.

ACS medicinal chemistry letters

Wurz RP, Pettus LH, Ashton K, Brown J, Chen JJ, Herberich B, Hong FT, Hu-Harrington E, Nguyen T, St Jean DJ, Tadesse S, Bauer D, Kubryk M, Zhan J, Cooke K, Mitchell P, Andrews KL, Hsieh F, Hickman D, Kalyanaraman N, Wu T, Reid DL, Lobenhofer EK, Andrews DA, Everds N, Guzman R, Parsons AT, Hedley SJ, Tedrow J, Thiel OR, Potter M, Radinsky R, Beltran PJ, Tasker AS.
PMID: 26396685
ACS Med Chem Lett. 2015 Jul 27;6(9):987-92. doi: 10.1021/acsmedchemlett.5b00193. eCollection 2015 Sep 10.

In nonsmall cell lung cancer (NSCLC), the threonine(790)-methionine(790) (T790M) point mutation of EGFR kinase is one of the leading causes of acquired resistance to the first generation tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib. Herein, we describe...

Cite
Wurz RP, Pettus LH, Ashton K, et al. Oxopyrido[2,3-d]pyrimidines as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors. ACS Med Chem Lett. 2015;6(9):987-92doi: 10.1021/acsmedchemlett.5b00193.
Wurz, R. P., Pettus, L. H., Ashton, K., Brown, J., Chen, J. J., Herberich, B., Hong, F. T., Hu-Harrington, E., Nguyen, T., St Jean, D. J., Tadesse, S., Bauer, D., Kubryk, M., Zhan, J., Cooke, K., Mitchell, P., Andrews, K. L., Hsieh, F., Hickman, D., Kalyanaraman, N., Wu, T., Reid, D. L., Lobenhofer, E. K., Andrews, D. A., Everds, N., Guzman, R., Parsons, A. T., Hedley, S. J., Tedrow, J., Thiel, O. R., Potter, M., Radinsky, R., Beltran, P. J., & Tasker, A. S. (2015). Oxopyrido[2,3-d]pyrimidines as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors. ACS medicinal chemistry letters, 6(9), 987-92. https://doi.org/10.1021/acsmedchemlett.5b00193
Wurz, Ryan P, et al. "Oxopyrido[2,3-d]pyrimidines as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors." ACS medicinal chemistry letters vol. 6,9 (2015): 987-92. doi: https://doi.org/10.1021/acsmedchemlett.5b00193
Wurz RP, Pettus LH, Ashton K, Brown J, Chen JJ, Herberich B, Hong FT, Hu-Harrington E, Nguyen T, St Jean DJ, Tadesse S, Bauer D, Kubryk M, Zhan J, Cooke K, Mitchell P, Andrews KL, Hsieh F, Hickman D, Kalyanaraman N, Wu T, Reid DL, Lobenhofer EK, Andrews DA, Everds N, Guzman R, Parsons AT, Hedley SJ, Tedrow J, Thiel OR, Potter M, Radinsky R, Beltran PJ, Tasker AS. Oxopyrido[2,3-d]pyrimidines as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors. ACS Med Chem Lett. 2015 Jul 27;6(9):987-92. doi: 10.1021/acsmedchemlett.5b00193. eCollection 2015 Sep 10. PMID: 26396685; PMCID: PMC4569876.
Copy Download .nbib Format: NLM
Glucocorticoids with different chemical structures but similar glucocorticoid receptor potency regulate subsets of common and unique genes in human trabecular meshwork cells.

BMC medical genomics

Nehmé A, Lobenhofer EK, Stamer WD, Edelman JL.
PMID: 19744340
BMC Med Genomics. 2009 Sep 10;2:58. doi: 10.1186/1755-8794-2-58.

BACKGROUND: In addition to their well-documented ocular therapeutic effects, glucocorticoids (GCs) can cause sight-threatening side-effects including ocular hypertension presumably via morphological and biochemical changes in trabecular meshwork (TM) cells. In the present study, we directly compared the glucocorticoid receptor...

Cite
Nehmé A, Lobenhofer EK, Stamer WD, et al. Glucocorticoids with different chemical structures but similar glucocorticoid receptor potency regulate subsets of common and unique genes in human trabecular meshwork cells. BMC Med Genomics. 2009;2:58doi: 10.1186/1755-8794-2-58.
Nehmé, A., Lobenhofer, E. K., Stamer, W. D., & Edelman, J. L. (2009). Glucocorticoids with different chemical structures but similar glucocorticoid receptor potency regulate subsets of common and unique genes in human trabecular meshwork cells. BMC medical genomics, 258. https://doi.org/10.1186/1755-8794-2-58
Nehmé, Alissar, et al. "Glucocorticoids with different chemical structures but similar glucocorticoid receptor potency regulate subsets of common and unique genes in human trabecular meshwork cells." BMC medical genomics vol. 2 (2009): 58. doi: https://doi.org/10.1186/1755-8794-2-58
Nehmé A, Lobenhofer EK, Stamer WD, Edelman JL. Glucocorticoids with different chemical structures but similar glucocorticoid receptor potency regulate subsets of common and unique genes in human trabecular meshwork cells. BMC Med Genomics. 2009 Sep 10;2:58. doi: 10.1186/1755-8794-2-58. PMID: 19744340; PMCID: PMC2749862.
Copy Download .nbib Format: NLM
AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research

Giffin MJ, Cooke K, Lobenhofer EK, Estrada J, Zhan J, Deegen P, Thomas M, Murawsky CM, Werner J, Liu S, Lee F, Homann O, Friedrich M, Pearson JT, Raum T, Yang Y, Caenepeel S, Stevens J, Beltran PJ, Canon J, Coxon A, Bailis JM, Hughes PE.
PMID: 33203642
Clin Cancer Res. 2021 Mar 01;27(5):1526-1537. doi: 10.1158/1078-0432.CCR-20-2845. Epub 2020 Nov 17.

PURPOSE: Small-cell lung cancer (SCLC) is an aggressive neuroendocrine tumor with a high relapse rate, limited therapeutic options, and poor prognosis. We investigated the antitumor activity of AMG 757, a half-life extended bispecific T-cell engager molecule targeting delta-like ligand...

Cite
Giffin MJ, Cooke K, Lobenhofer EK, et al. AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer. Clin Cancer Res. 2020;27(5):1526-1537doi: 10.1158/1078-0432.CCR-20-2845.
Giffin, M. J., Cooke, K., Lobenhofer, E. K., Estrada, J., Zhan, J., Deegen, P., Thomas, M., Murawsky, C. M., Werner, J., Liu, S., Lee, F., Homann, O., Friedrich, M., Pearson, J. T., Raum, T., Yang, Y., Caenepeel, S., Stevens, J., Beltran, P. J., Canon, J., Coxon, A., Bailis, J. M., & Hughes, P. E. (2021). AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(5), 1526-1537. https://doi.org/10.1158/1078-0432.CCR-20-2845
Giffin, Michael J, et al. "AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,5 (2021): 1526-1537. doi: https://doi.org/10.1158/1078-0432.CCR-20-2845
Giffin MJ, Cooke K, Lobenhofer EK, Estrada J, Zhan J, Deegen P, Thomas M, Murawsky CM, Werner J, Liu S, Lee F, Homann O, Friedrich M, Pearson JT, Raum T, Yang Y, Caenepeel S, Stevens J, Beltran PJ, Canon J, Coxon A, Bailis JM, Hughes PE. AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer. Clin Cancer Res. 2021 Mar 01;27(5):1526-1537. doi: 10.1158/1078-0432.CCR-20-2845. Epub 2020 Nov 17. PMID: 33203642.
Copy Download .nbib Format: NLM
Showing 1 to 4 of 4 entries